From Venice to Munich, follow the story of Alessandro Nicoli, a PhD student whose path into science was anything but linear. In this episode, he shares how a love of chemistry, the guidance of key mentors, and a leap into computational modeling led him to tackle one of biology’s greatest puzzles: olfactory GPCRs. Discover how AlphaFold, molecular dynamics, and curiosity-driven research are reshaping the way we study G protein-coupled receptors.

This week's Terry's Corner with Dr. Terry Kenakin delivers a game-changing framework for teams grappling with the gap between in vitro potency and in vivo performance.

This fundamental disconnect between the lab and the boardroom is precisely where programs get stuck—not because of bad science, but because companies find themselves throwing more money and people at problems that could be solved with better systems. This reactive approach, driven by a "go fast" mindset, burns through precious capital and time, leaving both scientific teams and investors frustrated.

From cryptic binding sites to ligand‑specific signaling, uncover how GPCR dynamics redefine drug discovery strategies and decision‑making.

Should we start research with the model, not the molecule? Dr. Alex Serafini explains how building backwards may be the future of GPCR-driven pain therapy.

Allostery isn’t just an advanced concept—it’s essential to understanding efficacy, ligand bias, and receptor behavior in real-world systems.

Explore how GPCRs function as dynamic allosteric machines in this expert-level breakdown from Dr. Terry Kenakin. Learn how probe dependence, cryptic binding sites, and conformational changes impact drug discovery and therapeutic design.

Discover how RGS proteins like RGS4 are reshaping our understanding of GPCRs and chronic pain. Dr. Alex Serafini explains the quiet power of GPCR regulation.

GPCRs pose a critical challenge in drug discovery: a vast therapeutic potential with many targets yet to be explored.  35% of...

Dr. Alex Serafini turned chronic pain into a research mission. Discover how personal experience shaped his work on GPCRs, RGS proteins, and new pain models.

Welcome GPCR Fans,   Every discovery-phase decision you make shapes your entire pipeline trajectory—and understanding when equilibrium...

Kenakin’s kinetic insights help you translate assay readouts into actionable knowledge that keeps your programs focused and moving efficiently toward clinical relevance.

That’s why this week at Dr. GPCR, we’re focusing on the hidden risks that undermine progress and how the right frameworks can keep your pipeline moving forward.

Sokhom Pin explains why staying in GPCR research during its “unpopular” phase helped him become a sought-after expert today.

Sokhom Pin shares how he built a thriving GPCR research team at Alkermes through trust, culture, and empowerment-driven leadership.

In Terry Kenakin’s latest lecture from the Emerging Drug Hunter series, he invites you into a thought-provoking reevaluation of one of pharmacology’s most misleading concepts: the myth of high and low-affinity binding sites.

Our CSO, Maria, has recently traveled to the US to attend the ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025 , a conference organized by...

Sokhom Pin shares how he earned a PhD while working in biotech, designing a custom program that defied academic convention.

Is Your GPCR Program Slowing Down—Even With Good Data? You’re not alone. Most teams don’t stall because the science is weak. They stall...

In Terry Kenakin’s latest foundational lesson from Terry’s Corner, he unpacks the art and science of pharmacologic modeling. This isn’t just theory—it's the essential framework used to interpret experimental data, anticipate system-wide drug effects, and design smarter trials.

The latest Terry’s Corner unlocks clinical forecasting tools few scientists truly master.

Welcome Back, Discovery Drivers   Terry’s Corner is live, on-demand pharmacology built for drug discovery. Yamina’s Corner opens for strategic consulting, and our partner Celtarys unveils a robust TR-FRET assay for CBRs. Plus: must-read chemokine and PTH1R papers, and new momentum across biotech—from Superluminal to Neurocrine to novel GLP-1 contenders. Dr.GPCR Updates Terry’s Corner is Live - Pharmacology at your fingertips Terry’s Corner is now open! Explore 10 on-demand l

Terry’s Corner — a new platform where GPCR scientists can sharpen their thinking, expand their toolkit, and learn directly from Dr. Terry Kenakin. Ten on-demand courses are live now, built to challenge assumptions and bring clarity to the complex, evolving world of GPCR pharmacology.

If you’ve read our previous post, you probably know what CELT-335 is and its high affinity for the cannabinoid 1 receptor (CB1R). During...